Possible Anandamide and Palmitoylethanolamide involvement in human stroke

Marcello Naccarato*1, Daniela Pizzuti2, Stefania Petrosino3, Marco Simonetto1, Laura Ferigo1, Fabio Chiodo Grandi1, Gilberto Pizzolato1 and Vincenzo Di Marzo3

Abstract

Background: Endocannabinoids (eCBs) are ubiquitous lipid mediators that act on specific (CB1, CB2) and non-specific (TRPV1, PPAR) receptors. Despite many experimental animal studies proved eCB involvement in the pathogenesis of stroke, such evidence is still lacking in human patients. Our aim was to determine eCB peripheral levels in acute stroke patients and evaluate their relationship with clinical disability and stroke volume.

Methods: A cohort of ten patients with a first acute (within six hours since symptoms onset) ischemic stroke and a group of eight age- and sex-matched normal subjects were included. Groups were also matched for metabolic profile. All subjects underwent a blood sample collection for anandamide (AEA), 2-arachidonoylglycerol (2-AG) and palmitoylethanolamide (PEA) measurement; blood sampling was repeated in patients on admission (T0), at 6 (T1) and 18 hours (T2) thereafter. Patients neurological impairment was assessed using NIHSS and Fugl-Meyer Scale arm subitem (FMSa); stroke volume was determined on 48 h follow-up brain CT scans. Blood samples were analyzed by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry.

Results: 1) T0 AEA levels were significantly higher in stroke patients compared to controls. 2) A significant inverse correlation between T0 AEA levels and FMSa score was found. Moreover a positive correlation between T0 AEA levels and stroke volume were found in stroke patients. T0 PEA levels in stroke patients were not significantly different from the control group, but showed a significant correlation with the NIHSS scores. T0 2-AG levels were lower in stroke patients compared to controls, but such difference did not reach the significance threshold.

Conclusions: This is the first demonstration of elevated peripheral AEA levels in acute stroke patients. In agreement with previous murine studies, we found a significant relationship between AEA or PEA levels and neurological involvement, such that the greater the neurological impairment, the higher were these levels.

Background

During the last decade numerous studies have addressed the role of the endocannabinoid (eCB) system in different pathological conditions. Endocannabinoids (eCBs), e.g. anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are lipid mediators synthesized “on demand” that inhibit neurotransmitter (glutamate and GABA) release and modulate neuroinflammation by activating specific CB1 (highly expressed in the CNS, where they mediate the psychotropic effects of ∆9-tetrahydrocannabinol) and CB2 (expressed by immune cells, including brain resident microglial cells) receptors, respectively. Cannabinoid receptor-inactive eCB-related molecules, e.g. palmitoylethanolamide (PEA), also exert neuroprotective effects[1-3], presumably by preventing mast cell degranulation [4], and directly activating peroxisome proliferator-activated receptor (PPAR)-α [5], or by enhancing the effects of AEA on cannabinoid receptors, transient receptor potential vanilloid type-1 (TRPV1) channels and PPAR-γ receptors [6].

Previous murine and cell culture studies on stroke and hypoxia postulated a neuroprotective role of eCBs, given their ability to decrease NMDA-mediated toxicity in vascular penumbra through a CB2-mediated mechanism [7]. Increases of AEA content, of the AEA biosynthetic precursors (e.g. N-acyl phosphatidylethanolamines), and of

* Correspondence: marcello.naccarato@katamail.com
1 Department of Medical, Technological and Translational Sciences, Neurology Unit, University of Trieste, Strada di Fiume 447, 34100 Trieste (TS), Italy
Full list of author information is available at the end of the article

© 2010 Naccarato et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
CB₁ receptors expression in ischemic brain regions of murine stroke models have been described [8-11]. CB₁ knockout mice develop larger stroke volumes than wild-type animals, with consequent increased post-stroke disability and mortality [12]. In addition, CB₁ agonist administration was associated with a decrease of infarct volume and with an improvement of clinical symptoms in stroke-treated mice [13]. Interestingly, there is evidence that also low-doses of CB₁ receptor antagonists, such as rimonabant, reduce infarct volume in stroke models [9,10,14,15], possibly by enhancing TRPV1-mediated actions [14]. It has been also suggested that part of the neuroprotective effects of CB₁ receptor agonists in stroke is due to their capability of lowering body temperature, and that CB₄, as opposed to CB₂, receptors might otherwise play a counterprotective role in cerebral ischemia [15].

Indeed, also CB₂ receptors have been implicated in the pathogenesis of stroke. Since such receptors are particularly expressed on activated microglia and peripheral immune cells (mastcells, macrophages and lymphocytes), they may act by modulating the inflammatory response to stroke [16], which is triggered 24-48 hours after symptoms onset and is mainly responsible for the delayed neuronal death [17]. Indeed CB₂ agonists administration was associated with a reduction of infarct volume and neurological impairment in murine models of stroke and cerebral ischemia [15,18]. However, such evidence is still lacking in humans, despite the fact that a single case report described an increase of AEA and PEA content in cerebral Artery (MCA) territory with at least arm impairment and symptoms onset ≤ 6 hours before admission. A follow-up brain CT scan was performed 48 hours after admission. Control subjects (Group B), after written informed consent, underwent blood sampling for eCB and laboratory analysis; their BMI was also calculated.

Endocannabinoid determination
Blood was collected in EDTA and immediately centrifuged at 400 g for 30 min at room temperature. Extraction, purification of AEA, 2-AG and PEA, and their quantification by isotope-dilution liquid chromatography-atmospheric pressure chemical ionization-mass spectrometric analysis were performed as previously described [22].

Brain CT analysis
Twenty-eight contiguous 5 mm-thick axial slices, covering the whole brain, were obtained for each patient with a multislice TOSHIBA AQUILION scanner, with 120 kV, 250 mA and 2 s acquisition time (Toshiba Medical Systems). Thereafter, using Analyze 4.5 (Biomedical Imaging Resource, Mayo University) and a semi-automated routine, two blinded examiners (FCG and GP) calculated the total lesion volume in mL, as the sum of the stroke area in each slice multiplied by slice thickness (Fig. 1).

Statistical analysis
Using the SPSS 13.0 statistical software package (SPSS Inc.), inter-group differences were evaluated with the Mann-Whitney U test, while the Spearman rho test was used to evaluate correlations between eCBs plasma levels and the clinical and radiological data.

Results
Groups were comparable with regard to age, gender, BMI, and laboratory findings (Tab. 1). Mean AEA, PEA, and 2-AG blood levels in the control group (Group B) were similar to previously reported values [22-25] and correlated with total cholesterolemia and BMI. At T0, AEA plasma levels in the stroke patient group were significantly higher than in the control group (Tab. 1 and Fig. 2; Mann-Whitney U test: p < 0.05). In addition, AEA levels at T0 showed a significant inverse relationship with the FMSa scores (Fig 3; Spearman rho = -0.819, p = 0.004), so that patients with greater neurological impairment (lower FMSa score) had higher AEA levels. There was also a positive correlation between T0 plasma AEA levels and the volume of the ischemic brain region on CT scans (Spearman rho = 0.667, p < 0.05).
No significant differences between groups in PEA plasmatic levels were observed. Nevertheless, there was a significant correlation between PEA levels at T0 and the NIHSS scores (Fig. 4; Spearman rho = 0.823, p = 0.003), such that the greater the neurological impairment, the higher the PEA levels.

Plasma 2-AG levels were lower in stroke patients, but group differences did not reach statistical significance. No significant differences in AEA or PEA content were observed at later time-points (T1 and T2) between groups (Tab. 1).

Discussion

Previous studies showed an involvement of the eCB system in various neurological conditions [26]. To our knowledge, this is the first study addressing the potential involvement of eCBs and a related mediator in acute stroke in a cohort of human patients.

Since eCBs have been proposed to act as local mediators and not as circulating hormones, the physiopathological consequences in stroke of the observed alterations in eCB plasma levels cannot be easily inferred. Nevertheless, there are several reports of changes in plasma endocannabinoid levels in patients affected by various neurological and neuropsychiatric conditions, including multiple sclerosis [27], Huntington’s chorea [28], migraine [29,30], schizophrenia [22], depression [31] and anorexia nervosa [23]. Therefore, although one would expect that such conditions alter endocannabinoid signalling mostly in the brain, there is clearly a “spill-over” effect to the peripheral circulation, the extent of which often reflects, as in the present case, the severity of CNS pathology. Accordingly, endocannabinoid blood levels usually are 1-2 orders of magnitude lower than brain levels. Interestingly, a recent review by Maccarrone’s group emphasized the relationship between brain diseases and endocannabinoid peripheral dysregulation, showing that peripheral eCBs could be a marker of CNS pathologies [32].

Peripheral AEA levels at T0 were significantly increased in stroke patients and showed a positive correlation with neurological disability and stroke volume. Likewise, plasma PEA levels showed a significant correlation with neurological disability. There was also a trend to reduced 2-AG levels in stroke patients. On the other hand, AEA and PEA levels at later time-points were not different between groups. These observations parallel the findings of a single case study in a patient with hemi-
spheric stroke in which AEA and PEA contents were pre-
cociously increased in microdyalisates of tissue
surrounding the ischemic lesion [19]. They also parallel
several studies showing early increases of AEA and PEA,
but reduced 2-AG, in ischemic brain regions in animal
models of global and focal cerebral ischemia [33]. Inter-
estingly, Maccarrone’s group found an increase of CSF
and plasmatic AEA, but not 2-AG, content in multiple
sclerosis patients during relapses [27]. In addition, the
same group recently demonstrated that an increase of
striatal AEA levels may result in a decrease of 2-AG bi-
synthesis, thus suggesting an inverse relationship
between AEA and 2-AG levels, under certain conditions
[34].

Table 1: Demographic and laboratory data of stroke patients and control subjects.

|                      | Group A                        | Group B                        | p       |
|----------------------|--------------------------------|--------------------------------|---------|
| Sex (M/F)            | 5/5                            | 4/4                            | n.s.    |
| Age yrs. (mean ± SD) | 70 ± 13                        | 70 ± 12                        | n.s.    |
| NIHSS score (median ± SD; range) | 22 ± 10; 3-29 | -                              | -       |
| Fugl-Meyer Scale-arm score (median ± SD; range) | 11.50 ± 9; 8-44 | -                              | -       |
| CT ischemic area Volume (mL; mean ± SD) | 76.10 ± 43.46 | -                              | -       |
| Body Mass Index (mean ± SD) | 25.20 ± 2.74 | 24.63 ± 2.39                   | n.s.    |
| Cholesterol (mmol/L - mean ± SD) | 11.69 ± 2.31 | 11.64 ± 2.04                   | n.s.    |
| Triglycerides (mmol/L - mean ± SD) | 6.97 ± 2.33 | 6.82 ± 1.00                    | n.s.    |
| Blood Glucose (mmol/L - mean ± SD) | 5.61 ± 0.71 | 5.77 ± 0.74                    | n.s.    |
| AEA T0 (pmol/lipid mg - mean ± SD) | 3.42 ± 2.71 | 1.81 ± 1.53                    | 0.026   |
| AEA T1 (pmol/lipid mg - mean ± SD) | 2.87 ± 2.34 | -                              | n.s.    |
| AEA T2 (pmol/lipid mg - mean ± SD) | 3.11 ± 2.72 | -                              | n.s.    |
| PEA T0 (pmol/lipid mg - mean ± SD) | 2.47 ± 0.96 | 2.05 ± 0.31                    | n.s.    |
| PEA T1 (pmol/lipid mg - mean ± SD) | 2.28 ± 1.01 | -                              | n.s.    |
| PEA T2 (pmol/lipid mg - mean ± SD) | 2.17 ± 0.67 | -                              | n.s.    |
| 2-AG T0 (pmol/lipid mg - mean ± SD) | 3.42 ± 7.22 | 6.80 ± 9.50                    | n.s.    |
| 2-AG T1 (pmol/lipid mg - mean ± SD) | 4.65 ± 4.98 | -                              | n.s.    |
| 2-AG T2 (pmol/lipid mg - mean ± SD) | 3.29 ± 3.10 | -                              | n.s.    |

Demographic, clinical, radiological data and endocannabinoid or PEA plasma levels in stroke patients (Group A, at T0, T1, and T2 time-points) and control subjects (Group B). p = p values (Mann-Whitney U test); n.s. = not significant.

Figure 2 Box-plot of plasma AEA levels in control and stroke patient groups (at T0). * At T0, mean plasma AEA levels were significantly higher in the stroke patients group (p < 0.05, Mann-Whitney U test).

Figure 3 Scatterplot of plasma AEA levels versus aFMS score in stroke patients at T0. Significant inverse correlation between AEA levels and aFMS score (Spearman rho = -0.819, p = 0.004).
Since AEA acts as an endogenous agonist for CB1 receptors, exerts a possible protective effect, or whether it is part of the mechanisms leading to neurological damage during stroke. Therefore, further studies are warranted to address the therapeutic potential of eCB system modulation in stroke patients, as already explored in several (pre)clinical studies on other neurological diseases, such as multiple sclerosis, Alzheimer's disease, and brain trauma [26,36]. Finally, the role and mechanism of action of PEA in neuroprotection against cerebral ischemia also needs to be more deeply investigated.

Conclusions

Our findings in stroke patients show an early increase in plasma AEA content which correlates with neurological disability and infarct volume. Our study extends previous observations from the case report by Schäbitz and colleagues [19], showing a relationship between plasma AEA content and neurological disability. However, our present findings do not allow to determine, for instance, whether the increase in AEA levels is a consequence of stroke and exerts a possible protective effect, or whether it is part of the mechanisms leading to neurological damage during stroke. Therefore, further studies are warranted to address the therapeutic potential of eCB system modulation in stroke patients, as already explored in several (pre)clinical studies on other neurological diseases, such as multiple sclerosis, Alzheimer's disease, and brain trauma [26,36]. Finally, the role and mechanism of action of PEA in neuroprotection against cerebral ischemia also needs to be more deeply investigated.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MN was involved in experimental planning, clinical data collection, data analysis and manuscript writing. DP was involved in experimental planning and endocannabinoid determination. SP performed endocannabinoid determination and contributed to data analysis. MS and LF were involved in clinical evaluation, clinical data collection and manuscript editing. FCG performed neuroimaging data analysis, contributed to data collection and manuscript editing. GP contributed to experimental planning, neuroimaging data analysis and manuscript editing. VDM contributed to experimental planning, data analysis and manuscript writing. All authors read and approved the final manuscript.

Acknowledgements and Funding

This study has been funded by Giuliani Farmaceutici s.p.a. and Epitech Italia. The authors would thank the Radiology (Prof. M. Cova) and Immunotransfusion Departments (Dott. L. Uxa) of the Azienda Ospedaliero-Universitaria of Trieste for their kind help in providing the radiological data and contributing to the blood samples analysis.

Author Details

1Department of Medical, Technological and Translational Sciences, Neurology Unit, University of Trieste, Strada di Fiume 447, 34100 Trieste (TS), Italy, 2Department of Surgical and Gastroenterological Sciences, University of Padova, Via Giustinianini 5, Padova (PD), Italy and 3Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, Via Campi Flegrei 34, Pozzuoli (NA), Italy

Received: 6 April 2010 Accepted: 14 May 2010
Published: 14 May 2010

References

1. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, Leon A: The ALIamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 1996, 93: 3984-3989.
2. Lombardi G, Miglio G, Vanaldi F, Minassi A, Appendino G: Oxyhomologation of the amide bond potentiates neuroprotective effects of the endolipid N-palmitoylethanolamine. J Pharmacol Exp Ther 2007, 320: 599-606.
3. Schomacher M, Müller HD, Sommer C, Schwab S, Schabitz WR: Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res 2008, 1240: 213-220.
4. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995, 92: 3376-3380.
5. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D: The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005, 67: 15-19.
6. Costa B, Cornelli F, Bettoni L, Colleoni M, Giannoni G: The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain.
involvement of CB1, TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008, 139:541-550.

7. Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol 2006, 69:691-696.

8. Muthian S, Rademaker DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 2004, 129:743-750.

9. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HHO. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 2004, 88:1159-1167.

10. Jin K, Mao XO, Goldsmith PC, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002, 22:9771-9779.

11. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999, 19:2987-2995.

12. Pergoni S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, Sala M. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br J Pharmacol 2000, 144:727-735.

13. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF. Modulation of the balance between cannabinoid CB1 and CB2 receptor activation during cerebral ischemic/reperfusion injury. Neurosci 2006, 129:743-750.

14. Pegorini S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, Sala M. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br J Pharmacol 2000, 144:727-735.

15. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF. Modulation of the balance between cannabinoid CB1 and CB2 receptor activation during cerebral ischemic/reperfusion injury. Neurosci 2008, 152:753-760.

16. Ashton KC, Rahman IRA, Nair SM, Sutherland BA, Glass M, Appleton I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 2007, 412:114-117.

17. Saleh A, Schroeter M, Ringelstein A, Hartung HP, Rorick M, Moomaw CJ, Walker M. Increased plasma concentrations of 2-arachidonoylglycerol in peripheral blood of patients with ischemic stroke. Cancer Res 2001, 61:6483-6486.

18. Battista N, Bernardi G, Bernardini S, Martino G, Di Montezemolo N, Corasaniti MT, Maccarrone M, Bagetta G. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. FEBS J 2007, 274:4464-4475.

19. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002, 22:9771-9779.

20. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999, 19:2987-2995.

21. Pergoni S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, Sala M. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br J Pharmacol 2000, 144:727-735.

22. Zolese G, Bacchetti T, Ambrosini A, Wozniak M, Bertoli E, Ferretti G. Increased plasma concentrations of Palmitoylethanolamide, an endogenous fatty acid amide, affect oxidative damage of human low-density lipoproteins: An in vitro study. Atherosclerosis 2005, 182:47-55.

23. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V, Battistini L, Bernardi G, Bernardini S, Martino G, Maccarrone: The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007, 130:2543-2553.

24. Battista N, Bari M, Tarditi A, Mariotti C, Baczchod-Lévê AC, Zuccato C, Finazzi-Agro A, Gentinetti S, Peschanski M, Di Donato S, Cattaneo E, Maccarrone M. Severe deficiency of the fatty acid amide hydroxase (FAAH) activity segregates with the Huntington’s disease mutation in peripheral lymphocytes. Neurobiol Dis 2007, 27:108-116.

25. Cupini LM, Bari M, Battista N, Argioli G, Finazzi-Agro A, Calabresi P, Maccarrone M. Biochemical changes in endocannabinoid system are espresse in platelets of female but not male migraineurs. Cephalalgia 2006, 26:277-281.

26. Rossii C, Pini LA, Cupini ML, Calabresi P, Sarchielli P. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol 2008, 64:1-8.

27. Hill MN, Miller GE, Ho WS, Gorgalka BB, Hillard CJ. Serum endocannabinoid contents altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008, 41:48-53.

28. Centonze D, Battistini L, Maccarrone M. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des 2008, 14:2370-2442.

29. Pellegrini-Giampietro DE, Mannaioni P, Bagetta G. Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death. FEBS Journa 2009, 276:6-12.

30. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, Gasperi V, Prosperetti C, Bernardi G, Finazzi-Agro A, Cravatt BF, Centonze D. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008, 11:152-159.

31. Re C, Barbero R, Milo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 2007, 173:21-30.

32. Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007, 36:68-74.

Cite this article as: Naccarato et al., Possible Anandamide and Palmitoylethanolamide involvement in human stroke Lipids in Health and Disease 2010, 9:47

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit